Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73


A second patient cured of HIV infection: hopes and limitations.

Scarborough RJ, Goguen RP, Gatignol A.

Virologie (Montrouge). 2019 Jun 1;23(3):1-4. doi: 10.1684/vir.2019.0778. No abstract available.


A second patient cured of HIV infection: hopes and limitations.

Scarborough RJ, Goguen RP, Gatignol A.

Virologie (Montrouge). 2019 Jun 1;23(3):145-148. doi: 10.1684/vir.2019.0777. French. No abstract available.


Small RNAs to treat human immunodeficiency virus type 1 infection by gene therapy.

Goguen RP, Malard CM, Scarborough RJ, Gatignol A.

Curr Opin Virol. 2019 May 18;38:10-20. doi: 10.1016/j.coviro.2019.04.003. [Epub ahead of print] Review.


B-cell non-Hodgkin lymphoma discovery after observation of a platelet satellitism around atypical lymphocytes.

Gatignol A, Amirault M, Legac É, Decker J.

Ann Biol Clin (Paris). 2019 Apr 1;77(2):191-195. doi: 10.1684/abc.2018.1406.


ADAR1 and PKR, interferon stimulated genes with clashing effects on HIV-1 replication.

Radetskyy R, Daher A, Gatignol A.

Cytokine Growth Factor Rev. 2018 Apr;40:48-58. doi: 10.1016/j.cytogfr.2018.03.007. Epub 2018 Mar 26. Review.


Higher Cytopathic Effects of a Zika Virus Brazilian Isolate from Bahia Compared to a Canadian-Imported Thai Strain.

Alpuche-Lazcano SP, McCullogh CR, Del Corpo O, Rance E, Scarborough RJ, Mouland AJ, Sagan SM, Teixeira MM, Gatignol A.

Viruses. 2018 Jan 27;10(2). pii: E53. doi: 10.3390/v10020053.


RNA Interference Therapies for an HIV-1 Functional Cure.

Scarborough RJ, Gatignol A.

Viruses. 2017 Dec 27;10(1). pii: E8. doi: 10.3390/v10010008. Review.


Inhibition of the inflammatory response to stress by targeting interaction between PKR and its cellular activator PACT.

Dabo S, Maillard P, Collados Rodriguez M, Hansen MD, Mazouz S, Bigot DJ, Tible M, Janvier G, Helynck O, Cassonnet P, Jacob Y, Bellalou J, Gatignol A, Patel RC, Hugon J, Munier-Lehmann H, Meurs EF.

Sci Rep. 2017 Nov 23;7(1):16129. doi: 10.1038/s41598-017-16089-8.


Tribute to Mark Wainberg.

Arts EJ, Gatignol A, Mouland AJ, Liang C, Götte M, Soudeyns H.

Retrovirology. 2017 Jun 28;14(1):38. doi: 10.1186/s12977-017-0361-6. No abstract available.


Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy.

Scarborough RJ, Adams KL, Del Corpo O, Daher A, Gatignol A.

J Vis Exp. 2016 Sep 5;(115). doi: 10.3791/54486.


Effective inhibition of HIV-1 production by short hairpin RNAs and small interfering RNAs targeting a highly conserved site in HIV-1 Gag RNA is optimized by evaluating alternative length formats.

Scarborough RJ, Adams KL, Daher A, Gatignol A.

Antimicrob Agents Chemother. 2015 Sep;59(9):5297-305. doi: 10.1128/AAC.00949-15. Epub 2015 Jun 15.


HIV and Ribozymes.

Scarborough RJ, Gatignol A.

Adv Exp Med Biol. 2015;848:97-116. doi: 10.1007/978-1-4939-2432-5_5. Review.


HIV-1 RRE RNA acts as an RNA silencing suppressor by competing with TRBP-bound siRNAs.

Daniels SM, Sinck L, Ward NJ, Melendez-Peña CE, Scarborough RJ, Azar I, Rance E, Daher A, Pang KM, Rossi JJ, Gatignol A.

RNA Biol. 2015;12(2):123-35. doi: 10.1080/15476286.2015.1014759.


A Conserved Target Site in HIV-1 Gag RNA is Accessible to Inhibition by Both an HDV Ribozyme and a Short Hairpin RNA.

Scarborough RJ, Lévesque MV, Boudrias-Dalle E, Chute IC, Daniels SM, Ouellette RJ, Perreault JP, Gatignol A.

Mol Ther Nucleic Acids. 2014 Jul 29;3:e178. doi: 10.1038/mtna.2014.31.


HIV-1 translation and its regulation by cellular factors PKR and PACT.

Burugu S, Daher A, Meurs EF, Gatignol A.

Virus Res. 2014 Nov 26;193:65-77. doi: 10.1016/j.virusres.2014.07.014. Epub 2014 Jul 23. Review.


Design and evaluation of clinically relevant SOFA-HDV ribozymes targeting HIV RNA.

Scarborough RJ, Lévesque MV, Perreault JP, Gatignol A.

Methods Mol Biol. 2014;1103:31-43. doi: 10.1007/978-1-62703-730-3_3.


Ribosomal proteins L5 and L11 co-operatively inactivate c-Myc via RNA-induced silencing complex.

Liao JM, Zhou X, Gatignol A, Lu H.

Oncogene. 2014 Oct 9;33(41):4916-23. doi: 10.1038/onc.2013.430. Epub 2013 Oct 21.


The PKR activator, PACT, becomes a PKR inhibitor during HIV-1 replication.

Clerzius G, Shaw E, Daher A, Burugu S, Gélinas JF, Ear T, Sinck L, Routy JP, Mouland AJ, Patel RC, Gatignol A.

Retrovirology. 2013 Sep 11;10:96. doi: 10.1186/1742-4690-10-96.


RNA-induced silencing complex (RISC) Proteins PACT, TRBP, and Dicer are SRA binding nuclear receptor coregulators.

Redfern AD, Colley SM, Beveridge DJ, Ikeda N, Epis MR, Li X, Foulds CE, Stuart LM, Barker A, Russell VJ, Ramsay K, Kobelke SJ, Li X, Hatchell EC, Payne C, Giles KM, Messineo A, Gatignol A, Lanz RB, O'Malley BW, Leedman PJ.

Proc Natl Acad Sci U S A. 2013 Apr 16;110(16):6536-41. doi: 10.1073/pnas.1301620110. Epub 2013 Apr 2.


The multiple functions of TRBP, at the hub of cell responses to viruses, stress, and cancer.

Daniels SM, Gatignol A.

Microbiol Mol Biol Rev. 2012 Sep;76(3):652-66. doi: 10.1128/MMBR.00012-12. Review.


Enhancement of replication of RNA viruses by ADAR1 via RNA editing and inhibition of RNA-activated protein kinase.

Gélinas JF, Clerzius G, Shaw E, Gatignol A.

J Virol. 2011 Sep;85(17):8460-6. doi: 10.1128/JVI.00240-11. Epub 2011 Apr 13. Review.


In vitro and in vivo cleavage of HIV-1 RNA by new SOFA-HDV ribozymes and their potential to inhibit viral replication.

Lainé S, Scarborough RJ, Lévesque D, Didierlaurent L, Soye KJ, Mougel M, Perreault JP, Gatignol A.

RNA Biol. 2011 Mar-Apr;8(2):343-53. Epub 2011 Mar 1.


Multiple levels of PKR inhibition during HIV-1 replication.

Clerzius G, Gélinas JF, Gatignol A.

Rev Med Virol. 2011 Jan;21(1):42-53. doi: 10.1002/rmv.674. Epub 2010 Dec 7. Review.


A role for human Dicer in pre-RISC loading of siRNAs.

Sakurai K, Amarzguioui M, Kim DH, Alluin J, Heale B, Song MS, Gatignol A, Behlke MA, Rossi JJ.

Nucleic Acids Res. 2011 Mar;39(4):1510-25. doi: 10.1093/nar/gkq846. Epub 2010 Oct 23.


Hepatitis C virus controls interferon production through PKR activation.

Arnaud N, Dabo S, Maillard P, Budkowska A, Kalliampakou KI, Mavromara P, Garcin D, Hugon J, Gatignol A, Akazawa D, Wakita T, Meurs EF.

PLoS One. 2010 May 11;5(5):e10575. doi: 10.1371/journal.pone.0010575.


ADAR1 interacts with PKR during human immunodeficiency virus infection of lymphocytes and contributes to viral replication.

Clerzius G, Gélinas JF, Daher A, Bonnet M, Meurs EF, Gatignol A.

J Virol. 2009 Oct;83(19):10119-28. doi: 10.1128/JVI.02457-08. Epub 2009 Jul 15.


Characterization of the TRBP domain required for dicer interaction and function in RNA interference.

Daniels SM, Melendez-Peña CE, Scarborough RJ, Daher A, Christensen HS, El Far M, Purcell DF, Lainé S, Gatignol A.

BMC Mol Biol. 2009 May 7;10:38. doi: 10.1186/1471-2199-10-38.


TRBP control of PACT-induced phosphorylation of protein kinase R is reversed by stress.

Daher A, Laraki G, Singh M, Melendez-Peña CE, Bannwarth S, Peters AH, Meurs EF, Braun RE, Patel RC, Gatignol A.

Mol Cell Biol. 2009 Jan;29(1):254-65. doi: 10.1128/MCB.01030-08. Epub 2008 Oct 20.


Interactions between the double-stranded RNA-binding proteins TRBP and PACT define the Medipal domain that mediates protein-protein interactions.

Laraki G, Clerzius G, Daher A, Melendez-Peña C, Daniels S, Gatignol A.

RNA Biol. 2008 Apr-Jun;5(2):92-103. Epub 2008 Apr 8.


Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC.

Castanotto D, Sakurai K, Lingeman R, Li H, Shively L, Aagaard L, Soifer H, Gatignol A, Riggs A, Rossi JJ.

Nucleic Acids Res. 2007;35(15):5154-64. Epub 2007 Jul 26.


Transcription of HIV: Tat and cellular chromatin.

Gatignol A.

Adv Pharmacol. 2007;55:137-59. Review. No abstract available.


Small interfering RNAs against the TAR RNA binding protein, TRBP, a Dicer cofactor, inhibit human immunodeficiency virus type 1 long terminal repeat expression and viral production.

Christensen HS, Daher A, Soye KJ, Frankel LB, Alexander MR, Lainé S, Bannwarth S, Ong CL, Chung SW, Campbell SM, Purcell DF, Gatignol A.

J Virol. 2007 May;81(10):5121-31. Epub 2007 Mar 14.


New pandemics: HIV and AIDS, HCV and chronic hepatitis, influenza virus and flu.

Gatignol A, Dubuisson J, Wainberg MA, Cohen EA, Darlix JL.

Retrovirology. 2007 Feb 1;4:8.


Trafficking of HIV-1 RNA is mediated by heterogeneous nuclear ribonucleoprotein A2 expression and impacts on viral assembly.

Lévesque K, Halvorsen M, Abrahamyan L, Chatel-Chaix L, Poupon V, Gordon H, DesGroseillers L, Gatignol A, Mouland AJ.

Traffic. 2006 Sep;7(9):1177-93.


Cell-specific regulation of TRBP1 promoter by NF-Y transcription factor in lymphocytes and astrocytes.

Bannwarth S, Lainé S, Daher A, Grandvaux N, Clerzius G, Leblanc AC, Hiscott J, Gatignol A.

J Mol Biol. 2006 Feb 3;355(5):898-910. Epub 2005 Nov 28.


Low TRBP levels support an innate human immunodeficiency virus type 1 resistance in astrocytes by enhancing the PKR antiviral response.

Ong CL, Thorpe JC, Gorry PR, Bannwarth S, Jaworowski A, Howard JL, Chung S, Campbell S, Christensen HS, Clerzius G, Mouland AJ, Gatignol A, Purcell DF.

J Virol. 2005 Oct;79(20):12763-72.


TRBP, a regulator of cellular PKR and HIV-1 virus expression, interacts with Dicer and functions in RNA silencing.

Haase AD, Jaskiewicz L, Zhang H, Lainé S, Sack R, Gatignol A, Filipowicz W.

EMBO Rep. 2005 Oct;6(10):961-7.


Regulation of human immunodeficiency virus type 1 gene expression by clade-specific Tat proteins.

Desfosses Y, Solis M, Sun Q, Grandvaux N, Van Lint C, Burny A, Gatignol A, Wainberg MA, Lin R, Hiscott J.

J Virol. 2005 Jul;79(14):9180-91.


HIV-1 TAR RNA: the target of molecular interactions between the virus and its host.

Bannwarth S, Gatignol A.

Curr HIV Res. 2005 Jan;3(1):61-71. Review.


Astrocyte infection by HIV-1: mechanisms of restricted virus replication, and role in the pathogenesis of HIV-1-associated dementia.

Gorry PR, Ong C, Thorpe J, Bannwarth S, Thompson KA, Gatignol A, Vesselingh SL, Purcell DF.

Curr HIV Res. 2003 Oct;1(4):463-73. Review.


Identification of Staufen in the human immunodeficiency virus type 1 Gag ribonucleoprotein complex and a role in generating infectious viral particles.

Chatel-Chaix L, Clément JF, Martel C, Bériault V, Gatignol A, DesGroseillers L, Mouland AJ.

Mol Cell Biol. 2004 Apr;24(7):2637-48.


Additive activity between the trans-activation response RNA-binding protein, TRBP2, and cyclin T1 on HIV type 1 expression and viral production in murine cells.

Battisti PL, Daher A, Bannwarth S, Voortman J, Peden KW, Hiscott J, Mouland AJ, Benarous R, Gatignol A.

AIDS Res Hum Retroviruses. 2003 Sep;19(9):767-78.


The TAR RNA-binding protein, TRBP, stimulates the expression of TAR-containing RNAs in vitro and in vivo independently of its ability to inhibit the dsRNA-dependent kinase PKR.

Dorin D, Bonnet MC, Bannwarth S, Gatignol A, Meurs EF, Vaquero C.

J Biol Chem. 2003 Feb 14;278(7):4440-8. Epub 2002 Dec 9.


Frequency of mutations in the early growth response 2 gene associated with peripheral demyelinating neuropathies.

Vandenberghe N, Upadhyaya M, Gatignol A, Boutrand L, Boucherat M, Chazot G, Vandenberghe A, Latour P.

J Med Genet. 2002 Dec;39(12):e81. No abstract available.


Differential regulation of HIV-1 clade-specific B, C, and E long terminal repeats by NF-kappaB and the Tat transactivator.

Roof P, Ricci M, Genin P, Montano MA, Essex M, Wainberg MA, Gatignol A, Hiscott J.

Virology. 2002 Apr 25;296(1):77-83.


Organization of the human tarbp2 gene reveals two promoters that are repressed in an astrocytic cell line.

Bannwarth S, Talakoub L, Letourneur F, Duarte M, Purcell DF, Hiscott J, Gatignol A.

J Biol Chem. 2001 Dec 28;276(52):48803-13. Epub 2001 Oct 18.


Two dimerization domains in the trans-activation response RNA-binding protein (TRBP) individually reverse the protein kinase R inhibition of HIV-1 long terminal repeat expression.

Daher A, Longuet M, Dorin D, Bois F, Segeral E, Bannwarth S, Battisti PL, Purcell DF, Benarous R, Vaquero C, Meurs EF, Gatignol A.

J Biol Chem. 2001 Sep 7;276(36):33899-905. Epub 2001 Jul 3.


Characterization of TRBP1 and TRBP2. Stable stem-loop structure at the 5' end of TRBP2 mRNA resembles HIV-1 TAR and is not found in its processed pseudogene.

Duarte M, Graham K, Daher A, Battisti PL, Bannwarth S, Segeral E, Jeang KT, Gatignol A.

J Biomed Sci. 2000 Nov-Dec;7(6):494-506.


Tat as a transcriptional activator and a potential therapeutic target for HIV-1.

Gatignol A, Jeang KT.

Adv Pharmacol. 2000;48:209-27. Review. No abstract available.


Supplemental Content

Loading ...
Support Center